Facebook Twitter Instagram You Tube Pinterest LinkedIn RSS Podcasts Video Library Blog
 - Northwestern Memorial Hospital - Chicago

A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1

A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1

The primary purpose of this study is to evaluate the safety and efficacy of a protease inhibitor given with IFN-alfa 2b and ribavirin.

Inclusion Criteria:

Naïve No cirrhotics:

  • GT1 –ANC>1200/mm
  • -PLT >90,000
  • -Hb >13g/dL males>12g/dL females
  • -AFP <20 ng/mL If >20, neg. imaging within 6 mo.

Sponsor:

Schering Plough Research Institute

Principle Investigator:

Steve Flamm, MD

Cost:

None

Contact:

Noreen Khan
312-503-0122

Last UpdateMarch 25, 2011
top